touchONCOLOGY joins Dr Yelena Janjigian (Medical Oncologist, Chief, Memorial Sloan Kettering Cancer Center, New York, NY, USA) at ASCO 2021 to discuss durvalumab in gastric cancer and the MATTERHORN study.
The abstract ‘A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03) (NCT04379596)’ (abstract number TPS261) was presented at the 2021 ASCO Annual Meeting.
Citation: J Clin Oncol 39, 2021 (suppl 3; abstr TPS261)
1. What is the rationale for the addition of durvalumab to neoadjuvant-adjuvant FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer? (00:15-01:45)
2. What are the eligibility criteria and key inclusion criteria for the MATTERHORN study? (01:45-04:30)
3. Could you give us a brief overview of the study design? (04:30-06:26)
4. What are the primary and secondary study endpoints? (06:26-06:50)
5. When are initial results expected? (06:50-07:10)
Disclosures: Research Funding: NCI, Department of Defense, Cycle for Survival, Fred’s Team, RGENIX, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly and Merck. Advisory Boards/Consulting: Bristol-Myers Squibb, Merck Serono, Merck, Eli Lilly, Daiichi-Sankyo, Pfizer, Bayer, Imugene, AstraZeneca, Zymeworks Inc., Seattle Genetics, Basilea Pharmaceutica, RGENIX (stock options and consulting).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.
Filmed in coverage of the 2021 ASCO Annual Meeting.
Share this Video
Related Videos In Gastrointestinal Oncology
Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]
Alvaro Arjona-Sanchez, ESMO 2022: HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant HIPEC in patients with locally advanced colon cancer
Peritoneal metastasis in locally advanced colon cancer has a poor prognosis from 3 years post surgical resection. Dr Alvaro Arjona-Sanchez (Institute of Biomedical Research IMIBIC, University Hospital Reina Sofia, Cordoba, Spain) joins touchONCOLOGY to discuss the HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally […]
Myriam Chalabi, ESMO 2022: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study
Neoadjuvant immunotherapy has shown promising responses in several cancer types. In this touchONCOLOGY interview Dr Myriam Chalabi (Netherlands Cancer Institute, Amsterdam, Netherlands) discusses the NICHE-2 study results, investigating patients with non-metastatic deficient DNA mismatch repair (dMMR) colon cancer, treated with one dose of ipilimumab and two doses of nivolumab and underwent surgery ≤6 weeks of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!